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Abstract Mitochondrial health is critically dependent on the
ability of mitochondria to undergo changes in mitochondrial
morphology, a process which is regulated by mitochondrial
shaping proteins. Mitochondria undergo fission to generate
fragmented discrete organelles, a process which is mediated
by the mitochondrial fission proteins (Drp1, hFIS1, Mff and
MiD49/51), and is required for cell division, and to remove
damaged mitochondria by mitophagy. Mitochondria undergo
fusion to form elongated interconnected networks, a process
which is orchestrated by the mitochondrial fusion proteins
(Mfn1, Mfn2 and OPA1), and which enables the replenish-
ment of damaged mitochondrial DNA. In the adult heart, mi-
tochondria are relatively static, are constrained in their move-
ment, and are characteristically arranged into 3 distinct sub-
populations based on their locali ty and function
(subsarcolemmal, myofibrillar, and perinuclear). Although
the mitochondria are arranged differently, emerging data sup-
ports a role for the mitochondrial shaping proteins in cardiac
health and disease. Interestingly, in the adult heart, it appears
that the pleiotropic effects of the mitochondrial fusion
proteins, Mfn2 (endoplasmic reticulum-tethering,
mitophagy) and OPA1 (cristae remodeling, regulation of apo-
ptosis, and energy production) may play more important roles
than their pro-fusion effects. In this review article, we provide
an overview of the mitochondrial fusion and fission proteins
in the adult heart, and highlight their roles as novel therapeutic
targets for treating cardiac disease.
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Introduction to Mitochondrial Morphology
Mitochondrial health is critically dependent on the ability of
mitochondria to move and change their morphology. By un-
dergoing fission they generate fragmented discrete mitochon-
dria, a process which is regulated by the mitochondrial fission
proteins, dynamic-related peptide-1 (Drp1), human fission
protein-1 (hFis1), mitochondrial fission factor (Mff) and mi-
tochondrial dynamics proteins 49 and 51 (MiD49 and 51).
Mitochondrial fission is essential for cell division and is re-
quired to remove damaged mitochondria by mitophagy. In
contrast, the fusion of mitochondria generates elongated inter-
connected networks, a process which is orchestrated by the
mitochondrial fusion proteins, Mitofusins 1 and 2 (Mfn1 and
Mfn2), and optic atrophy protein-1 (OPA1), thereby enabling
the replenishment of damaged mitochondrial DNA [1] or fa-
cilitation of intracellular energy distribution [2].
Until recently, the investigation of mitochondrial morphol-
ogy had been largely confined to non-cardiac cells, in which
mitochondria have unrestrictedmovements and are distributed
throughout the cytoplasm into tubular networks. In contrast, in
the adult heart, mitochondria are relatively immobile, are
constrained in their ability to move, and are distributed into
3 distinct subpopulations based on their locality and function
(subsarcolemmal, myofibrillar, and perinuclear). Although the
mitochondria are arranged differently, emerging data supports
a role for the mitochondrial shaping proteins in cardiac health
and disease, with their effects on mediating changes in mito-
chondrial morphology playing a dominant role [3–6].
Interestingly, although the roles of the mitochondrial fission
proteins are closely related to their effects on mitochondrial
morphology in the adult heart, the mitochondrial fusion pro-
teins appear to have a number of pleiotropic non-fusion roles,
which may play more important roles in cardiac health and
disease than their pro-fusion effects (see Fig. 1). Mfn2 has
been reported to act as a tethering protein between mitochon-
dria and endoplasmic reticulum (ER) [7, 8], and to be a critical
mediator of mitophagy [9, 10]. Through its effects on cristae
remodeling, OPA1 has been shown to regulate mitochondrial
cytochrome C release and propensity to apoptosis, and facili-
tate mitochondrial energy production via its effects on the
respiratory supercomplexes. In this review article, we provide
an overview of the mitochondrial shaping proteins in the adult
heart, and highlight their roles as novel therapeutic targets for
treating cardiac disease. For more detailed general reviews on
mitochondrial morphology please refer to the following arti-
cles [11–16].
Mitochondrial Fission Proteins
The process of mitochondrial fission requires the activation
and dephosphorylation of cytosolic Drp1, which allows the
latter to translocate to mitochondria, and bind to docking re-
ceptors on the outer mitochondrial membrane (OMM). Here,
Drp1 oligomerises and forms a spiral around the mitochondri-
on, constricting it into two halves [17–20]. The roles the other
components of the mitochondrial fission machinery, hFis1,
Mff and MiD49/51, play in this process are currently under
investigation. The current evidence suggests that Mff [21–25]
and MiD49/51 [22, 26–31] act as docking proteins on the
OMM for Drp1, and that hFis1 plays a regulatory role in
mediating mitochondrial fission [32, 33]. Interestingly, Mff
and MiD49/51 have been reported to exert contrasting effects
on Drp1 GTPase activity at the OMM, with the former stim-
ulating, and the latter inhibiting Drp1 GTPase activity [22] -
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the resultant effect being dependant on the stoichiometric
levels of the adaptors as well as the presence of other signals
[22]. Another layer of complexity is added with the existence
of different subpopulations of Drp1 in the cytosol (di-
mers or tetramers or high order equilibrium) [34–36]
and even multiple splice variants of Drp1 [37], whereby
recruitment of specific subpopulations of Drp1 by either
Mff or MiD49/51 result in different effects on mito-
chondrial morphology [23, 38]. A number of other pro-
teins have been shown to regulate mitochondrial fission
in non-cardiac cells including COX assembly factor
ccdc56 [39], the OMM protein FUNDC1 [40–42] and
the myeloid cell leukemia factor 1 (Mcl-1) protein [43].
The ER and cytoskeleton have recently been demonstrated
to contribute to the mitochondrial fission process. Actin poly-
merisation by the ER-associated inverted formin-2 (INF2)
[44–46] has been shown to provide the force required for
partial constriction of the mitochondria, an event which has
been reported to facilitate the translocation of cytosolic Drp1
to these pre-constriction contact sites in the OMM.Drp1 trans-
location from the cytosol to the OMM has also been demon-
strated to be mediated by other components of the cytoskele-
ton including septins [47]. Transient de novo assembly of F-
actin on the OMM has been shown to mediate Drp1-mediated
fission [48], in a manner that is synergistic with Mff [49].
Inhibiting actin polymerization, myosin IIA, or the formin
INF2 can also reduce this Drp1/actin interaction [49].
The regulation of Drp1 activity is under the control of a
large number of post-translational modifications including
SUMOylation [50], phosphorylation [51–53], ubiquitination
[54], S-nitrosylation [55], and O-GlcNAcylation [56]. The
phosphorylation of Ser-637 by protein kinase A (PKA) [51,
53], calcium (Ca2+)/calmodulin-dependent protein kinase
(CaM Kinase) [57], and Proto-oncogene serine/threonine-
protein kinase Pim-1 (Pim1) [58] has been shown to prevent
the mitochondrial translocation of Drp1. In contrast, the phos-
phorylation of Ser-616 by Cdk1/cyclin B (a key mitotic ki-
nase) has been reported to promote mitochondrial fission by
Drp1 during mitosis [59, 60]. Under conditions of high cyto-
solic Ca2+, dephosphorylation of Drp1 at Ser-637 by calcine-
urin induces mitochondrial fission [51, 52, 61–63]. The abla-
tion of calcineurin in skeletal muscle leads to Ser-637
hyperphosphorylation of Drp1 causing elongation of mito-
chondria into ‘power-cable’-shaped filaments and increased
mitochondrial respiration [64]. In hyperglycemic conditions,
O-GlcNAcylation of OPA1 [65] and Drp1 [56] causes dephos-
phorylation of Ser-637 and the translocation of Drp1 to the
OMM.
More recently, it has also been demonstrated that AMPK
can phosphorylate Mff to trigger mitochondrial fission in
Fig. 1 Diagram depicting
interactions of the mitochondrial-
shaping proteins. The pro-fusion
proteins –Mfn1, Mfn2 and OPA1
function to fuse adjacent
mitochondria while Drp1
interacts with the docking
proteins – Mff, Fis1 or MiD49/51
to induce mitochondrial fission.
In addition to their profusion
effect, Mfn2 and OPA1 have
pleiotropic non-fusion actions.
RSC, respiratory supercomplex;
ER, endoplasmic reticulum; Mito,
mitochondria
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response to stress thereby initiating mitophagy of the mito-
chondrial fragments that have extensive damage [66].
Knockdown of the OMM-associated E3 ubiquitin ligase
MARCH5 was found to selectively inhibit ubiquitination
and proteasomal degradation of MiD49 leading to mitochon-
drial fission, a phenotype which was reversed by MARCH5
re-expression or MiD49 knockout [67].
Mitochondrial Fission, Apoptosis and Necroptosis
Drp1 has been demonstrated to co-localize with BAX at the
OMM in response to apoptotic stimuli [68]. Recent findings
have also invoked Drp1-dependent mitochondrial fission via
the involvement of MiD49/MiD51 as being pertinent for cris-
tae remodeling during intrinsic apoptosis [30]. Stimulated
emission depletion (STED) microscopy has shown that
BAX assembles with BAK and Drp1 in the form of a ring to
delineate the area required for mitochondrial outer membrane
permeabilization (MOMP) [69]. The area enclosed by the
BAX ring is devoid ofmitochondrial outer membrane proteins
such as Tom20, Tom22, and Sam50 [69]. Drp1 is also stabi-
lized by SUMOylation to promote mitochondrial fragmenta-
tion, loss of MMP and cytochrome C release [70], although
mitochondrial fragmentation does not necessarily equate to
cell death [71, 72]. Inhibition of Drp1 slows down rather than
fully inhibits apoptosis as other pro-apoptotic proteins may
still be released from the mitochondria [63, 73]. The opposite
holds true whereby Drp1-dependent mitochondrial fission can
occur independently of BAX, BAK and Apoptotic protease
activating factor 1 (APAF1) to amplify cell death caused by
certain factors such as BID and oxidative stress [74].
Downstream of BAX/BAK, the activation of apoptosis trig-
gers mitochondrial-anchored protein ligase (MAPL/MUL1)-
dependent SUMOylation of Drp1, a process requisite for sta-
bilization of ER/mitochondrial contact sites that act as
hotspots for mitochondrial constriction, calcium flux, cristae
remodeling, and cytochrome c release [75].
Another interesting observation with regard to the role of
Drp1 lies in its effects on necroptosis – a pathway of pro-
grammed necrosis. Earlier studies suggested the plausible
role of Drp1 in mediating mitochondrial fragmentation
following recruitment by the RIP3-PGAM5 complex
[76–79]. Later studies have however, refuted this claim [80,
81]. Using arenobufagin- and staurosporine -treated HCT116
cells – a human colon cell line, it was reported that
PGAM5L, but not PGAM5S constitutes a prerequisite for
the activation of BAX and dephosphorylation of Drp1 for
intrinsic apoptosis execution [82].
Mitochondrial Fission and Mitophagy
Mitochondrial fission is also essential for the degradation and
removal of damaged mitochondria by mitophagy. Down-
regulation of Drp1 induces mitochondrial elongation, impairs
mitochondrial autophagy, and prompts mitochondrial dys-
function, leading to cardiac dysfunction and increased suscep-
tibility to ischemia/reperfusion [83]. Nonetheless, the duration
of Drp1 downregulation used in this study was a prolonged
period (at least 72 h in cardiomyocytes; 4 weeks tamoxifen
injection in Drp1-CKO mice; 12-week-old Drp1-hetCKO
mice) [83], highlighting the detrimental effects of chronic in-
hibition of Drp1. Moreover, the PTEN-induced putative ki-
nase (PINK1) serves as a pro-fission signal, independently of
Parkin [84]. A reduced level of mitochondrial division still
persists even in the absence of Drp1 and is negatively regu-
lated by Parkin [85]. Under normal conditions, the scaffold
protein A-kinase anchoring protein 1 (AKAP1) recruits pro-
tein kinase A (PKA) to the outer mitochondrial membrane to
phosphorylate and inhibit Drp1. Following cellular damage,
PINK1 triggers PKA displacement from AKAP1 to ensure
fission of damaged mitochondria for organelle degradation
[84].
Mitochondrial Fusion Proteins
The fusion of 2 adjacent mitochondria to a single organelle
requires the initial fusion of the OMM under the regulation of
Mfn1 andMfn2, followed by the fusion of the inner mitochon-
drial membrane (IMM) by OPA1 (reviewed in [86]). The
mitofusins consist of a mitochondrial GTPase domain, a trans-
membrane domain, and a coiled-coil domain. The transmem-
brane domain functions to anchor these proteins to the mito-
chondrial membranes while the coiled-coil domains face the
cytosol and mediate the formation of homotypic (Mfn1–
Mfn1, Mfn2–Mfn2 and OPA1–OPA1) or heterotypic
(Mfn1–Mfn2) physical connections between adjacent mito-
chondria [11, 87, 88].
The Mitofusins Mfn1 and Mfn2
The GTPase activity of Mfn1 (which is higher than that for
Mfn2 [89]) is regulated by the binding of G-protein β2 sub-
unit to Mfn1 which decreases the motility of the latter and
facilitates its clustering at specific foci on the OMM, thereby
promoting the pro-fusion effects of Mfn1 [90]. Mfn2 expres-
sion is regulated by proteins linked to mitochondrial biogen-
esis such as PGC1-α and PGC1-β [91, 92]. The
ubiquitination of Mfn1 and Mfn2 promotes the degradation
of these proteins allowing unopposed mitochondrial fission
during the selective removal of dysfunctional mitochondria
by mitophagy [93, 94]. In addition, other components of the
OMM may interact with Mfn1 and Mfn2 to modulate mito-
chondrial morphology, such as appoptosin, a mitochondrial
carrier protein that is located in the IMM [95], and Smad2
which recruits the Rab and Ras Interactor 1 (RIN1) into a
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complex with Mfn2 to promote mitochondrial fusion [96].
More recent studies have unravelled the various pleiotropic
non-fusion roles of the mitochondrial fusion proteins, which
will be described in the following sections and summarised in
Table 1.
Mfn1 and Apoptotic Cell Death
Mitochondrial adaptation in mouse embryonic fibroblasts
(MEFs) and HeLa cells subjected to oxidative stress (exposed
to antimycin A (AMA), an inhibitor of electron transfer at
complex III) has been shown to be driven by mitochondrial
ubiqui t in l igase membrane-associated RING-CH
(MARCH5)-dependent quality control of acetylated Mfn1
[97]. In the presence of stress, Mfn1 is rapidly accumulated,
inducing mitochondrial hyperfusion. Following that,
MARCH5 binding to Mfn1 and its subsequent ubiquitylation
of Mfn1 is significantly enhanced. The acetylation status of
Mfn1 dictates the process of MARCH5 binding to Mfn1 and
its ubiquitylation. Although yet to be shown in the heart, ac-
celeration of Mfn1 degradation by MARCH5 under stress
remains an important quality control system that inhibits mi-
tochondrial aggregation and cell death [97].
Pleiotropic Non-fusion Role of Mfn2 as an ER-Tethering
Protein
Mfn2 also tethers the ER to the mitochondria for calcium
signaling from the ER to mitochondria [8]. This tethering
function allows formation of subcellular domains of high cal-
cium concentration close to the mitochondrial calcium
uniporter. In the heart, this allows calcium to be efficiently
transferred from the sarcoplasmic reticulum (SR) to the mito-
chondria which is crucial for cardiac contractility [98]. The
genetic ablation of Mfn2 in the heart disrupts the SR-
mitochondrial tethering and causes an impairment of Ca2+
signaling, diminished mitochondrial respiratory function and
deterioration in left ventricular (LV) systolic function [99].
Nevertheless, a quantitative electron microscopy (EM) analy-
sis showed an increase in the number of close contacts be-
tween the two organelles, in Mfn2−/− MEF cells [100], a
finding supported by multiple biochemical, morphological,
functional, and genetic data from other studies in subsequent
years [101–105]. Whether this discrepancy is cell-specific or
reliant on the presence of other specific proteins at the ER-
mitochondria interface remains to be further clarified. The
advent of more advanced imaging techniques may shed fur-
ther light on the function of Mfn2 as a tethering protein.
Table 1 Experimental studies implicating pleiotropic non-fusion roles of the mitochondrial fusion proteins
Study Condition Cell type Major non-fusion roles Other findings
Mfn1
[97] oxidative stress
(exposed to
antimycin
A (AMA))
MEFs and
HeLa
Mfn1 is rapidly accumulated, inducing
mitochondrial hyperfusion. Following that,
MARCH5 binding to Mfn1 and its subsequent
ubiquitylation of Mfn1 is significantly enhanced.
Mfn2
[98–105] Genetic ablation
of Mfn2
MEFs Reduced contact between mitochondria-ER Increased contact between
mitochondria-ER [101–105]
[106–108] Mfn2 co-localize with both BAX and BAK in
the OMM, impairing the fusion
Increased mPTP formation via the
combination of Mfn2, BAX and BAK
leads to cell death
[9, 93, 94,
109, 110]
Loss of
mitochondrial
potential
Removal of Mfn2 via ubiquitination and
proteosomal degradation inhibits its
pro-fusion activity
Mitochondrial fission occurs leading to
removal of the damaged
mitochondrion by mitophagy
Opa1
[113, 115] Loss of
mitochondrial
potential
SH-SY5Y
and MEFs
OPA1 is up-regulated by the NF-κB-responsive
promoter elements following Parkin recruitment
to maintain mitochondrial integrity and protect
from cell death [113].
Stress also induces the metallopeptidase
OMA1 to degrade the long isoforms
of OPA1 and causes mitochondrial
fragmentation for removal by
mitophagy [115].
[120] Apoptotic stimuli MEFs OPA1 prevents cytochrome c release to inhibit cell
death by ‘stapling’ the cristae junctions closed [120]
[122] Mice ESCs OPA1 also regulates formation and stability
of respiratory chain supercomplexes (RCS) –
components of the electron transport chain (ETC)
arranged to facilitate transfer of electrons, via
regulation of cristae morphology [122].
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Pleiotropic Non-fusion Role of Mfn2 in Apoptotic Cell
Death
Apoptosis or cardiomyocyte cell death has been implicated in
both acute and chronic heart diseases. The loss of myocardium
constitutes an important pathogenic process in the heart and,
hence, targeting the inhibition of apoptosis remains a viable
therapeutic option. Mfn2 has been demonstrated to co-localize
with both BAX and BAK in the OMM [68, 106]. BAX and
BAK are pro-apoptotic proteins and the binding of BAX to
Mfn2 impairs its pro-fusion capability [106]. Mfn2 also facil-
itates formation of the mitochondrial permeability transition
pore (MPTP) and decreases stability of the mitochondrial
membrane, thus promoting Drp1-mediated mitochondrial fis-
sion [107]. The absence of both BAX and BAK rescues the
cells from MPTP opening and cell death by necrosis, yet mi-
tochondrial fragmentation ensues [108]. Interestingly, genetic
ablation ofMfn2 also preventedMPTP opening, thus suggest-
ing that the combination of BAX-Mfn2 is sufficient to facili-
tate opening of the MPTP, which is achieved by forming
hemifusion-related holes used in the exchange of ions during
stress-induced MPTP opening [108]. These findings suggest
that the BAX/BAK-Mfn2 interaction may be sufficient to pro-
mote MPTP formation and increase susceptibility to cell
death. This notion was further supported using the BAX/
BAK/cyclophilin D triple knockout mice where MI size was
not substantially reduced when compared to the BAX/BAK
double knockout mice [108].
Pleiotropic Non-fusion Role of Mfn2 in Mitophagy
Recent data suggested that Mfn2 plays a pivotal role in the
removal of damage mitochondria by mitophagy. Chen et al.
[109] found that in damaged mitochondria with loss of mito-
chondrial membrane potential, Mfn2 is phosphorylated by
PINK1 at Thr-111 and Ser-442. This process then facilitates
binding of Parkin to the OMM which in turn ubiquitinates
Mfn2 [9]. The ubiquitination of Mfn2 inhibits its pro-fusion
activity allowing mitochondrial fission to take place, and also
recruits p62 to the OMM resulting in the selective removal of
the damaged mitochondria by mitophagy [9, 93, 94, 110].
Similarly, stress-induced JNK phosphorylation of Mfn2 leads
to recruitment of the ubiquitin ligase (E3) Huwe1/Mule/ARF-
BP1/HectH9/E3Histone/Lasu1 to Mfn2, with the BH3 do-
main of Huwe1 implicated in this interaction [109]. This re-
sults in ubiquitin-mediated proteasomal degradation of Mfn2,
leading to mitochondrial fission and enhanced apoptotic cell
death [109]. In addition, Wang et al. [10] have demonstrated
that Mfn2 plays a crucial role in autophagy as a mediator of
the of autophagosome-lysosome fusion, and deficiency of
Mfn2 in the heart was found to result in a cardiomyopathy.
Furthermore, age-induced reduction in Mfn2 levels in murine
skeletal muscle has been reported to impair both mitophagy
and mitochondrial quality, leading to an exacerbated age-
related mitochondrial dysfunction [111]. A compensatory
mechanism involving a ROS-dependent adaptive signaling
pathway through induction of HIF-1α and BNIP3 is triggered
as a result, raising the possibility of a similar feedback mech-
anism in the heart [111].
OPA1
The activity of the IMM pro-fusion protein OPA1 is regulated
by alternative splicing and post-translational modification (for
a more detailed review please see [112]). In addition to its pro-
fusion effects OPA1 has been demonstrated to display a num-
ber of pleiotropic non-fusion effects.
Pleiotropic Non-fusion Role of OPA1 in Mitophagy
Parkin has been shown to be recruited to the linear ubiquitin
assembly complex under conditions of stress that subsequently
increases linear ubiquitination of NF-κB essential modulator
(NEMO), which is essential for canonical NF-κB signaling.
OPA1 is then up-regulated by the NF-κB-responsive promoter
elements to maintain mitochondrial integrity and protect from
cell death. The lack of mitophagy, however, did not hamper the
Parkin-induced protection [113]. This finding however, has been
confounded by another study which did not find a major role for
Parkin in mediating OPA1 regulation [114]. Instead, the authors
found that the protective effect of Parkin may rather be related to
the ubiquitination of BAX and the limitation of its mitochondrial
translocation to themitochondria [114]. The authors also noted a
role of the non-classical NF-κB pathway in the regulation of
mitochondrial dynamics and OPA1 expression by showing that
the absence of IKKα induces lower levels of OPA1 and a
fragmented mitochondrial network [114]. Stress also induces
the metallopeptidase OMA1 to degrade the long isoforms of
OPA1 and causes mitochondrial fragmentation for removal by
mitophagy [115]. Nevertheless, whether the loss of OPA1 per se
will induce impairment of lysosome function in the heart, as can
be seen in neurodegenerative models [116], remains to be clar-
ified. Furthermore, in situ proximity ligation assay (PLA) in
murine lung epithelial MLE-12 cells and human cervical ade-
nocarcinoma HeLa cells showed that the hexameric intermem-
brane space protein, NDPK-D (or NM23-H4), binds cardiolipin
and facilitates its redistribution to the OMM as a form of
mitophagy-induction signal in association with OPA1 [117].
Pleiotropic Non-fusion Role of OPA1 in Cristae
Remodeling and Mitochondrial Apoptosis
The anti-apoptotic effects of OPA1 have been attributed to its
role in regulating mitochondrial cristae morphology and cyto-
chrome c distribution. The cristae or invaginations of the IMM
can be remodeled into either a narrow/tight junction or a
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widened gap by tBID. This action is essential for redistribu-
tion of cytochrome c from the intra-cristal space into the in-
termembrane space (IMS) to initiate apoptosis [118–121].
OPA1, conversely, prevents cytochrome c release to inhibit
cell death by ‘stapling’ these cristae junctions closed [120].
Pleiotropic Non-fusion Role of OPA1 in Cristae
Remodeling and Mitochondrial Respiratory Efficiency
OPA1 also regulates formation and stability of respiratory chain
supercomplexes (RCS) – components of the electron transport
chain (ETC) arranged to facilitate transfer of electrons, via reg-
ulation of cristae morphology [122]. This implicates OPA1 as a
regulator of mitochondrial respiration and a potential target for
regulating mitochondrial energy production. A genome-wide
RNA interference (RNAi) screen identified reactive oxygen spe-
cies modulator 1 (ROMO1) as a redox-regulated protein that is
able to oligomerize OPA1 for mitochondrial fusion and mainte-
nance of normal cristae morphology [123]. The presence of
oxidative stress induces the formation of high-molecular weight
ROMO1 complexes while knockdown of ROMO1 promoted
mitochondrial fission and loss of cristae, causing impaired mi-
tochondrial respiration and increased sensitivity to cell death
stimuli [123]. To adapt to cellular metabolic demand, changes
in energy substrate availability are sensed by mitochondrial
SLC25A transporters, which in turn regulate OPA1 oligomeri-
zation [124]. OPA1 oligomerizationmodulates cristae width and
regulates assembly of the ATP synthase, in a mitochondrial
fusion-independent manner. A fusion-incompetent form of
OPA1(Q297V) rescued OCR, ATP synthase assembly and cell
growth of OPA1 KO MEFs in galactose media, which forces
mitochondrial respiration for ATP production [124]. Data from
Tcells supports the link betweenmitochondrial morphology and
metabolism whereby fusion in memory T (TM) cells configures
electron transport chain (ETC) complex associations favoring
oxidative phosphorylation (OXPHOS) and FAO, while fission
in effector T (TE) cells leads to cristae expansion, reducing ETC
efficiency and promoting aerobic glycolysis [125].
Mitochondrial Morphology and the Adult Heart
Mitochondria in non-cardiac cells, cardiac cell lines, and neo-
natal cardiomyocytes are highly mobile and are distributed
throughout the cytosol in a filamentous network. In contrast,
in the adult cardiomyocyte, mitochondria are relatively static,
constrained in their ability to move, are in close contact with
each other, and are spatially arranged into 3 distinct sub-
populations according to locality and function. The majority
of the mitochondria are closely aligned adjacent to the myofi-
brils, with one or two mitochondria lying alongside each sar-
comere – these have been termed the interfibrillar mitochondria
(IFM), and are mainly involved in calcium signalling from the
SR to mitochondria and providing the energy required for car-
diomyocyte contraction [126, 127] (see Fig. 2). A smaller pop-
ulation of mitochondria are arranged in clusters beneath the
subsarcolemmal membrane and are believed to provide the
energy required for ion channel function and may be involved
with cell signaling – termed subsarcolemmal mitochondria
(SSM). The third subpopulation of mitochondria form clusters
either side of the nucleus, and are termed perinuclear mitochon-
dria (PNM), and are presumably required to provide energy for
transcription [126, 127] (see Fig. 2).
Although relatively immobile due to this characteristic spatial
arrangement, emerging data suggest that mitochondria in the
adult heart can undergo mitochondrial fusion and fission (see
reviews [3–5, 13, 128, 129]. The evidence for this has been
provided by electronmicroscopy [130–134], and using confocal
microscopy over a timescale ranging from seconds tominutes to
follow the movement of fluorescent marker such as the photo-
activatable mitochondrial green fluorescent protein [135, 136],
mitochondrial red and green fluorescent proteins [137–140],
Renilla luciferase complementation [141] to pH-sensitive fluo-
rescent mitochondrial probes [142, 143] between mitochondria.
Mitochondrial Fusion and Fission Proteins
in Cardiac Health and Disease
Cardiac Development and Growth
Mitochondrial Fission Proteins
During early cardiac differentiation, an upregulation of Drp1-
mediated mitochondrial fission coincides with removal of mi-
tochondria via SQSTM1 (sequestosome 1)-mediated
Fig. 2 Electron microscopy image showing the 3 subpopulations of
mitochondria in an adult cardiomyocyte. IFM, interfibrillar
mitochondria; PNM, perinuclear mitochondria; SSM, subsarcolemmal
mitochondria
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mitophagy [144]. Mitochondria are then repopulated in the
new myotube via PPARGC1A/PGC-1α (peroxisome
proliferator-activated receptor gamma, coactivator 1 alpha)-
mediated biogenesis, with a brisk upregulation of OPA1 levels
[144]. Genetic ablation of Drp1 has been shown to be embry-
onically lethal at day E12.5 [145]. In the adult heart, ablation
of Drp1 is associated with an impairment of mitophagy which
leads to cardiomyopathy [83], accentuating the crucial role of
Drp1-mediated fission in maintaining a healthy mitochondrial
network. Judging from these findings, the inhibition of Drp1
as a therapeutic approach may not be as straightforward due to
the fact that prolonged inhibition of Drp1 may be detrimental
to normal cardiac function.
Mitochondrial Fusion Proteins
The importance of mitochondrial fusion in cardiac development
has been delineated by death in utero during the mid-gestation
period upon genetic ablation of both Mfn1 and Mfn2 [88].
Cardiac-specific ablation of the mitofusins in the embryo causes
death at days E9.5–10.5 [146]. Kasahara et al. has demonstrated
that the levels ofMfn2 andOPA1 play an essential role in cardiac
development, with developmental arrest occurring at E13.5
when Mfn2 and OPA1 were absent. The observation postulates
an association between mitochondrial dynamics and cardiac dif-
ferentiation whereby calcium signaling linking calcineurin and
Notch signalling was affected by the ablation of these pro-fusion
proteins [147]. In the adult heart devoid ofMfn1, there appears to
be a lack of distinct cardiac phenotype [148]. Conditional abla-
tion of cardiac-specific Mfn2 (α-MHC-Cre), however, causes
mitochondria to become pleomorphic and slightly enlarged
while the LV exhibits modest hypertrophy with mild deteriora-
tion in systolic function [98, 99].Mfn2-deficientMEFs exhibited
a significantly increased respiration rate which correlated with
increased levels of mitochondrial markers (TOM20 and NAO)
as well as mitochondrial transcription factor A (TFAM) and per-
oxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) protein levels while total ATP content remains
unchanged [149]. The adaptive mechanism mediated by in-
creased level of PGC-1α andTFAM transcription factor prevents
an excessive depletion of mtDNA and severe impairment of cell
metabolism [149]. Combined ablation of bothMfn1 andMfn2 in
the adult murine heart induces a lethal cardiomyopathy after
several weeks, probably due to the mitochondrial fragmentation
present in these hearts [146, 150].
Cardiac metabolism changes in line with the growth and
maturation occurring in the first few days of post-natal
growth. Mitochondrial respiration switches from glycolysis
to oxidative phosphorylat ion during this period.
Mitochondria also change shapes from a fragmented pheno-
type to an elongated shape aligned alongside the myofibrils,
based on the increase in mitofusins [150] and reduction in
cardiac hypoxia-inducible factor (HIF) signalling. This shift
in HIF signaling also mediates an increase in fusion protein
expression from E16.5 in a stepwise manner through to P10.5
with the largest increase taking place between P0.5 and P2.5
in MFN1 and MFN2 and between P2.5 and P10.5 in OPA1
while no changes were detectable in fission protein Drp1 and
Fis1 levels over this time period [151]. Ablation of the
mitofusins from the heart at the late embryonic stage causes
severe mitochondrial dysfunction at 7 days (abnormal mito-
chondrial structure, down-regulated mitochondrial biogenesis
genes, reduced mitochondrial DNA), development of cardio-
myopathy, and all died before 14 days old [150]. The associ-
ation between Mfn1 and PGC-1α during the postnatal growth
of the heart lies in the ability of PGC-1α to stimulate the
transcription of Mfn1 gene by co-activating the orphan nucle-
ar receptor ERRα. Similarly, PGC-1α is crucial for a high-
level expression of nuclear- and mitochondrial-encoded genes
involved in mitochondrial energy transduction and OXPHOS
pathways, and for full respiratory capacity [152], albeit dis-
pensable for maintenance of mitochondria in the adult heart.
Parkin-mediated mitophagy as a form of organelle replace-
ment has been shown to be essential for normal perinatal car-
diac mitochondrial and metabolic maturation [153].
Engineered mutant Mfn2 expressed from birth which cannot
be PINK1-phosphorylated on Thr111 and Ser442 as required
for Mfn2-Parkin binding disrupts developmental perinatal
transformation of cardiac metabolism [153].
Stem Cell Differentiation into Cardiomyocytes
Cardiac stem cells differentiating into adult cardiomyocytes
experience a change in mitochondrial function and structure
to accommodate for the switch from anaerobic glycolysis to
oxidative phosphorylation, to support the increased metabolic
demands of the differentiated beating cardiomyocyte ([154];
reviewed in [155]). In line with the change in mitochondrial
metabolism, mitochondria change from a fragmented state
(lacking cristae) in the embryonic stem cells (ESC), to an
elongated state (with well-developed cristae), closely aligned
with the myofibrils of the differentiated contractile cardio-
myocyte [154]. This change in mitochondrial morphology is
due to decreased Drp1 and increased Mfn2. The presence of
the mitofusins constitutes a barrier to reprogramming whereby
removing Mfn1/2 inhibits the p53-p21 pathway and promotes
the conversion of somatic cells to a pluripotent state. The
ablation of the mitofusins facilitates the glycolytic metabolic
transition through the activation of the Ras-Raf and hypoxia-
inducible factor 1α (HIF1α) signalling [156]. Interestingly,
Kim et al. showed in the same year that Drp1 activation pro-
moted differentiation of C2C12 myoblasts induced by serum
starvation. Inhibiting mitochondrial fission in the same cell
type via mdivi-1 or Drp1K38A impairs myogenic maturation
further supporting the role of both fission and fusion in car-
diomyocyte differentiation [157]. A more recent study in
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Drosophila also demonstrated crosstalk between the fusion
components (ChChd3, OPA1 and Marf) and the Hippo path-
way in regulating cellular proliferation where a loss of fusion
impairs proliferation during development [158]. The conflict-
ing observations imply that the role of mitochondrial dynam-
ics in cardiac differentiation is cell-specific and the cellular
background (presence of certain mutations) may exert a more
prominent role than expected. More recently, it was demon-
strated that prohibitin 2 (PHB2) - a pleiotrophic factor mainly
localised in mitochondria, is upregulated in undifferentiated
mouse ES cells while differentiation causes the downregula-
tion of the level of PHB2. This varying expression of PHB2
affects mitochondrial function via modulation of OPA1 pro-
cessing, although the effects on OPA1 seem to be separate
from the differentiation of ES cells [159].
It is interesting to note that reprogramming a somatic cell
into induced pluripotent stem cells (iPSCs) requires an induc-
tion of genes involved in mitochondrial biogenesis (TFAM,
NRF1), mitochondrial fusion (MFN1, MFN2) and glycine
production while able to tolerate a certain degree of
OXPHOS defects [160]. Reprogramming MEFs to iPSCs
however, also induces a downregulation of the MAP kinase
phosphatase Dusp6 to subsequently activate ERK signalling
and promote a Drp1-dependent mitochondrial fission pathway
that is necessary for pluripotency [161].
Heart Failure
Mitochondrial Fission Proteins
A mutation in the Drp1 gene (C452F) in a mouse mutant,
Python, caused an autosomal dominant form of dilated cardio-
myopathy. The homozygous mutation was embryonically le-
thal but the heterozygous form achieved adulthood albeit it
developed a severe dilated cardiomyopathy after 11 weeks.
This cardiomyopathy was associated with reduced content of
mitochondrial respiratory enzymes and ATP. In terms of mito-
chondrial morphology, mitochondria of heterozygous Python
MEFs were abnormal with numerous long tubular mitochon-
dria whilst homozygous Python MEFs had grossly abnormal
mitochondria which appeared to be spherical and aggregated
[162]. A further study by the same group refined the details by
showing that the C452F mutation in mice not only increased
Drp1 GTPase activity but also conferred resistance to oligomer
disassembly, ultimately leading to impaired mitophagy, mito-
chondrial depolarization, aberrant calcium handling, impaired
ATP synthesis, and activation of sterile myocardial inflamma-
tion [163]. Interestingly, a single human mutation in Drp1
(A395D), lying close to the C452F mutation in the middle
domain of the protein was also previously described [164].
The mutant A395D protein is however defective for self-
assembly and GTP hydrolysis [165]. Mitochondrial fragmenta-
tion evoked by enhanced Drp1-mediated fission in Drosophila
cardiomyocytes did not adversely impact heart tube function
[166]. Likewise, mitochondrial polarization status assessed by
TMRE fluorescence was also not adversely impacted by Drp1-
induced fragmentation [166]. The discrepancy in these obser-
vations for Drp1 mutations may be attributed to various factors,
including: (1) species difference; (2) different Drp1 mutations
(3) different gene promoters used for cardiomyocyte-specific
gene manipulation.
In the SENP5-Tg (SENP5 (a SUMO isopeptidase) overex-
pressing) murine hearts, a decrease in SUMO attachment to
Drp1 has been detected, leading to an enlargement of mito-
chondria at the early developmental stage. This was also ac-
companied by decreased cardiomyocyte proliferation and ele-
vated apoptosis [167]. Excess mitochondrial fragmentation due
to an upregulation of Drp1 contributes to impaired mitophagy
and elevated mitochondrial ROS. Parkin is not abundant and
has been found to be dispensable for constitutive mitophagy in
normal hearts [168]. Removal of Drp1 by tamoxifen-inducible
knockout in the adult mouse hearts, however, not only
prevented mitochondrial fission, but also markedly upregulated
Parkin, thus provokingmitophagicmitochondrial depletion that
contributed to a lethal cardiomyopathy [168]. Concomitant
conditional Parkin deletion with Drp1 ablation in adult mouse
hearts prevented the upregulation of Parkin, while increasing 6-
week survival, with an improved ventricular ejection fraction,
mitigating adverse cardiac remodeling, and decreasing cardiac
myocyte necrosis and replacement fibrosis [168]. Short-term
observation of heart failure in mice subjected to transverse aor-
tic constriction (TAC), however, showed that Drp1-associated
mitochondrial autophagy is transiently activated and then
downregulated in the mouse heart in response to pressure over-
load [169]. Downregulation of mitochondrial autophagy in this
scenario plays an important role in mediating the development
of mitochondrial dysfunction and heart failure, which can be
reversed by injection of Tat-Beclin 1, a potent inducer of au-
tophagy [169]. It has also been reported in murine hearts sub-
jected to pressure overload that there is an aberrant activation of
MMP-9 causing degradation of the gap junction protein
connexin-43 (Cx-43) in the ventricular myocardium [170,
171]. The reduction in levels of Cx-43 was associated with
increased fibrosis and ventricular dysfunction in heart failure
[170]. Usage of the small molecule inhibitor of Drp1 –mdivi-1,
normalized the decreased ratio of MFN2 to Drp1 [172] as well
as the expression levels of MMP-9 and Cx-43, thus showing an
improved cardiac function [171, 173, 174]. The intricate link
between mitochondrial biogenesis and dynamics and
mitophagy can also be seen from the use of Brg1 (Brahma-
related gene 1) /Brm (Brahma) double mutant mice (cardio-
myocyte-specific and inducible deletion of the SWI/SNF
(SWItch/Sucrose Non-Fermentable) ATP-dependent chromatin
remodeling complexes BRG1 and BRM in adult mice) [175].
These double-mutant mice exhibited increased mitochondrial
biogenesis, increases in ‘mitophagy’, and late stage decrease in
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mitochondrial-shaping proteins that led to small, fragmented
mitochondria following which a severe cardiomyopathy and
death occur [175].
Mitochondrial Fusion Proteins
Cardiac ablation of both Mfn1 and Mfn2 causes a mild cardio-
myopathy [98, 99]. Cardiac ablation of Mfn2 alone in the adult
murine heart only manifests as increased sensitivity to acute IRI
and development of late-onset LV dysfunction at 17 months of
age. The underlying mechanisms associated with this include
impaired autophagy, defective lipid metabolism, and decreased
mitochondrial respiration (primarily at complex III) [10].
Silencing of MARF (mitochondrial assembly regulatory factor
– orthologue of mammalian, Mitofusin) and OPA1 in the
Drosophila fly heart tube leads to dilated cardiomyopathy, a
phenomenon which could be rescued by over-expressing either
of the human Mitofusins (MFN1 or MFN2) or superoxide dis-
mutase 1, implicating impaired mitochondrial fusion and oxi-
dative stress in the pathogenesis of the heart failure [176]. A
further study conducted by the same group refined the details
by demonstrating that scavenging ROS by overexpressing su-
peroxide dismutase (SOD) or suppressing ROMO1 prevented
mitochondrial and heart tube dysfunction provoked by OPA1
RNAi, but not by mitofusin/MARF RNAi. In contrast, enhanc-
ing the ability of endoplasmic/sarcoplasmic reticulum to handle
stress by expressing Xbp1, an ER stress-responsive transcrip-
tion factor, rescued the cardiomyopathy of mitofusin/MARF
insufficiency without improving that caused by OPA1 deficien-
cy [166]. This again reiterates, at least in Drosophila heart
tubes, the fact that mitochondrial fission per se does not always
lead to cardiac dysfunction. Rather, it is the co-occurrence of
mitochondrial fission with enhanced ROS and ER stress that
induces cardiomyopathy. Similarly, rat hearts followed for
twelve to eighteen weeks after myocardial infarction exhibited
a decrease in MFN2, an increase in Fis1, and no change in
OPA1 expression [177]. The lack of Mfn2 also impairs
Parkin-mediated mitophagy leading to an accumulation of
damaged ROS-producing organelles and progressive heart fail-
ure [9, 178]. To circumvent this, suppressing mitochondrial
ROS provides benefits in preventing depolarization of the mi-
tochondria, respiratory impairment and structural degeneration.
Nevertheless, it should be noted that suppression of mitochon-
drial ROS in these settings should be controlled as overly sup-
pressing mitochondrial ROS was associated with impaired sec-
ondary autophagic pathways, suggesting the importance of mi-
tochondrial ROS alongside mitochondrial dynamics in mediat-
ing mitophagy and minimize cardiac failure [179]. The lack of
Parkin and ensuing disruption of mitophagy causes an accumu-
lation of enlarged, hollow “donut” mitochondria with dilated
cardiomyopathy [180]. Induction of mitochondrial fission
prevented the cardiomyopathy and corrected mitochondrial
dysfunction demonstrating the link among improper mitochon-
drial fusion, defective mitophagy and organ dysfunction [180].
Levels of OPA1 were also found to be decreased in a post-
MI rat heart failure model and human dilated and ischemic
cardiomyopathy tissue samples [181]. Heterozygous levels of
OPA1 also reduced mitochondrial DNA copy number and
decreased expression of nuclear antioxidant genes at 3–
4 months [182]. Nevertheless, baseline cardiac function was
found to be normal in OPA1-deficient mice, although cardio-
myopathy associated with mitochondrial fragmentation and
impaired mitochondrial function developed at 12 months of
age [182]. The reason for the decline of OPA1 levels in heart
failure requires further investigation. Similarly during initial
compensatory cardiac hypertrophy, an increase in OPA1 and
decrease in Drp1 occur in concert with decreased Parkin and
Sirt1/AMPK-PGC-1α signalling, signifying a compromised
mitochondrial remodelling system [183]. A recent study by
Wai et al. demonstrated that dilated cardiomyopathy and heart
failure was induced when cardiac-specific ablation of Yme1l
in mice activated OMA1 and hastened OPA1 proteolysis,
leading to mitochondrial fragmentation and altered cardiac
metabolism [184]. This deleterious scenario was rescued by
OMA1 deletion, which prevented OPA1 cleavage [184].
Acute Ischemia-Reperfusion Injury and Cardioprotection
Mitochondrial Fission Proteins
Mitochondrial dysfunction induced by acute ischemia/
reperfusion injury (IRI) is a critical determinant of cardiomyo-
cyte death following acute myocardial infarction. In 2006,
Brady et al. first made the observation that mitochondria un-
dergo fission when HL-1 cardiac cells were subjected to sim-
ulated ischemia, generating fragmented mitochondria, a
change in mitochondrial morphology which persisted into
simulated reperfusion, and was reversed in the presence of
pharmacological inhibition of p38 MAPK [185]. Two years
later, Plotnikov et al. [186] noted that mitochondria in rat
primary renal tubular epithelium and fibroblasts also
underwent fragmentation during simulated IRI, and this effect
was prevented by pre-treating the cells with either SkQ1 (a
mitochondrial anti-oxidant), Li + (a non-specific GSK-3β in-
hibitor) or insulin. Whether mitochondrial fission induced by
acute IRI was merely an epiphenomenon or a determinant of
cell death in this setting, was investigated by our group, when
we found that genetic inhibition of Drp1 in HL-1 cardiac cells
(using a dominant-negative mutant of Drp1) [130], not only
inhibited the mitochondrial fission induced by acute IRI but
also reduced cell death in this setting, highlighting mitochon-
drial fission as a potential therapeutic target for
cardioprotection. Our group went on to demonstrate that mi-
tochondria in adult murine hearts also undergo fission in re-
sponse to acute IRI, and that preventing this using mdivi-1, a
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small molecule inhibitor of Drp1, attenuated the death of adult
cardiomyocytes subjected to simulated IRI and reduced
in vivo MI size in the adult murine heart following acute IRI
[130]. Subsequent studies have confirmed that adult cardiac
mitochondria undergo fission in response to acute IRI, and
that targeting Drp1 with dominant negative mutants [187],
siRNA [188], mdivi-1 [173, 189], P110 (a peptide inhibitor
of the interaction between hFis and Drp1) [190], or Dynasore
(a non-specific dynamin inhibitor) [191] reduced MI size in
small animal models of acute IRI. Pharmacological inhibition
of mitochondrial fission at the onset of reperfusion using
mdivi-1 [173], P110 [190] and most recently nanoparticle-
mediated drug delivery of Mdivi1 (which was shown to be
more effective than administering mdivi-1 alone [192], has
been shown in experimental studies to reduce MI size in small
animal ex and in vivo models of acute IRI, demonstrating a
clinically-relevant time-point for cardioprotection in AMI pa-
tients. However, a recent study in HL-1 cardiac cells failed to
demonstrate any benefit with mdivi-1 administered at the on-
set of reoxygenation, and actually showed an increase in cell
death – the reason for which is unclear [193]. Whether thera-
peutic inhibition of mitochondrial fission can reduce MI size
in a clinically-relevant large animal model remains to be de-
termined. Given the potential non-specific effects of mdivi-1
[194], novel, more -specific inhibitors of mitochondrial fission
are needed to translate this therapeutic approach into the clin-
ical setting. In this regard, the discovery of other components
of the mitochondrial fission machinery such as ER-mediated
mitochondrial pre-constriction and the Drp1 docking proteins
in the OMM, Mff and MiD49/51, may provide novel thera-
peutic targets for inhibiting mitochondrial fission. It is impor-
tant to appreciate that although acute inhibition of mitochon-
drial fission induced by acute IRI is cardioprotective, the
chronic inhibition of Drp1 may be detrimental to the heart as
the process of mitochondrial fission is necessary for the re-
moval of damaged mitochondria by mitophagy [112, 196].
This was nicely illustrated by Ikeda et al. [83] who demon-
strated that conditional cardiac-specific ablation of Drp1 in-
duced mitochondrial elongation, suppressed mitophagy, in-
creasedMPTP opening susceptibility, resulting in a cardiomy-
opathy and increased MI size following acute IRI.
There are several unanswered questions concerning mito-
chondrial fission as a mediator of cell death in acute IRI, and
as a target for cardioprotection. Firstly, the mechanism
through which acute IRI induces mitochondrial fission is not
clear - potential explanations include:
(1) mitochondrial ROS [186, 189] which is generated during
acute IRI is known to induce mitochondrial fission.
Plotnikov et al. showed that pre-treatment of SkQ1 (a mi-
tochondrial ROS scavenger) prevented the mitochondrial
fission induced by simulated IRI [186], and Zaja et al.
demonstrated that Trolox, a ROS scavenger, decreased
pSer616 Drp1 levels and mitochondrial fission in HL-1
cardiac cells following simulated IRI [189].
(2) cytosolic calcium overload which occurs during acute
IRI may activate calcineurin thereby dephosphorylating
and activating Drp1 [61, 195]. Hom et al. [196] demon-
strated in both neonatal and adult cardiomyocyte that
increasing cytosolic calcium concentration induced
Drp1-dependent mitochondrial fission.
Secondly, the mechanism through which inhibiting mito-
chondrial fission induced by acute IRI protects the heart is not
clear. We have shown that inhibiting mitochondrial fission
may protect the heart against acute IRI by decreasing MPTP
opening susceptibility [130], although the mechanisms
linking mitochondrial fission to MPTP opening remain un-
clear and need to be further investigated.
A number of signaling pathways and/or cardioprotective
interventions have been shown to inhibit Drp1-dependant mi-
tochondrial fission induced by acute IRI:
1. Wang et al. [195] demonstrated that the p53-
microRNA499-calcineurin-Drp1 axis operates in the
heart to mediate mitochondrial fission and cardiomyocyte
death in the setting of acute IRI in the heart, and thera-
peutic inhibition of this pathway was found to reduce MI
size in murine hearts.
2. Using H9C2 myoblasts, Kim et al. [197] found that the
mitochondrial scaffolding protein A-kinase anchoring
protein 121 (AKAP121) inhibits mitochondrial fission
following simulated IRI AKAP121 through PKA-
dependent inhibitory phosphorylation of Drp1 and PKA-
independent inhibition of Drp1-Fis1 interaction.
3. Pride et al. [198] have shown that nitrate-induce precon-
ditioning protect H9C2 myoblasts against simulated IRI
by activating PKA, phosphorylating Drp1 and inhibiting
mitochondrial fission induced by acute IRI.
4. Kuzumic et al. [199] demonstrated that trimetazidine
protected rat neonatal cardiomyocytes from palmitate-
induced mitochondrial fission and dysfunction.
5. Zaja et al. [189] found that cyclin dependent kinase 1
(Cdk1) and protein kinase C isoform delta (PKC-δ) bind
to and increased Drp1 activity, in the setting of simulated
IRI in HL-1 cardiac cells.
6. Using an experimental model of isoproterenol (β-adren-
ergic receptor agonist)-induced ischemic injury in the rat
heart, Xue et al. [200] demonstrated that vagal nerve stim-
ulation attenuated the expression of the mitochondrial fis-
sion proteins (Drp1, hFis1), preventedmitochondrial frag-
mentation and inhibited MPTP opening, and decreased
MI size, via the muscarinic-3 receptor/Ca2+/calmodulin-
dependent kinase kinase β/AMPK signaling pathway.
7. DJ-1, also known as Park7 (Parkinson’s Disease autoso-
mal recessive, early onset 7), is an evolutionarily
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conserved 189-amino acid protein, that has been shown to
protect the brain and heart against acute IRI through its
protective effects on mitochondrial function [201, 202].
Shimizu et al. [203] have demonstrated that DJ-1 reduces
MI size by modifying the SUMOylation (a post-
translational modification process in which small
ubiquitin-like modifier proteins are covalently and revers-
ibly conjugated to target proteins) of Drp1 and inhibiting
mitochondrial fission in the murine heart [203].
Mitochondrial Fusion Proteins
The roles of the mitochondrial fusion proteins Mfn1, Mfn2 and
OPA1 in susceptibility to acute IRI have been recently investi-
gated in HL-1 cardiac cells, neonatal rodent cardiomyocytes,
and adult rodent cardiomyocytes with both interesting and
sometimes surprising results. The over-expression of Mfn2 in
HL-1 cardiac cells was shown to induce mitochondrial elonga-
tion, lower MPTP opening susceptibility and reduce cell death
following simulated acute IRI [130], andMfn2 ablation in neo-
natal cardiomyocytes was shown to increase cell death follow-
ing simulated IRI [99], findings which are consistent with the
notion that mitochondrial fission induced by acute IRI is detri-
mental. However, in the adult heart, the genetic ablation of
either cardiac-specific Mfn1 or Mfn2 was found to have oppos-
ing and unexpected effects with pleomorphic mitochondria,
less MPTP opening and reduced cell death [107, 148, 204].
Similarly, although cardiac-specific ablation of both Mfn1 and
Mfn2 (DKO) resulted in mitochondrial fragmentation, de-
creased respiratory function, and impaired myocardial contrac-
tile function [205], it resulted in less MPTP opening and re-
duced MI size following acute IRI. The reason for the unex-
pected results of ablating Mfn1 and/or Mfn2 in the heart are not
known but may relate to pleiotropic effects of Mfn2. The ab-
sence of Mfn2 in the DKOmice increased the distance between
SR and mitochondria and resulted in less mitochondrial calcium
overload during acute IRI which may have, in part, contributed
to the protected phenotype observed in the DKO mice [205].
These findings suggest that the acute inhibition of Mfn2 during
acute IRI may provide a novel cardioprotective strategy and that
the mechanism underlying this beneficial effect appears to be
independent of its effects on mitochondrial morphology.
Partial ablation of OPA1 promotes formation of clusters of
fused mitochondria and altered cristae with increased mitochon-
drial size. Sensitivity toMPTP opening however, was decreased
[206]. OMA1 is activated in a BAX- and BAK-dependent fash-
ion [207]. Activated OMA1 cleaved OPA1, an event that is
critical for remodeling of mitochondrial cristae [207]. OMA1
knockdown in neuronal cells or renal proximal tubular cells
prevented OPA1 proteolysis, fragmentation of mitochondria,
cytochrome c release and cell death during ATP-depleted ische-
mia [208, 209]. The pro-survival kinase, Akt as well as its
pharmacological activator, EPO has also been postulated to con-
fer cardioprotection by means of elongating the mitochondria
via modulation of Mfn1 [210], a finding similarly recapitulated
by the pro-survival extracellular-signal-regulated kinase (ERK)
[211]. Recent studies in the liver demonstrated a downregulation
of SIRT1 following hepatic IRI, which was partially attributable
to activation of calpains [212], while genetic overexpression or
pharmacological activation of SIRT1 using resveratrol or
SRT1720 markedly suppressed defective autophagy, onset of
the mitochondrial permeability transition, and hepatocyte death
after I/R [213]. The studies also identified Mfn2 as a novel
target of SIRT1 in which SIRT1 deacetylates Mfn2 to mediate
autophagy induction [212, 213]. Male adult rats exposed to four
5-min cycles of limb ischemia interspersed by 5min of limb
reperfusion, immediately prior to myocardial ischemia and
120min of reperfusion (MI + RIPC group) experienced a small-
er infarct size (−28%), increased mitochondrial fusion protein
OPA1, and preserved mitochondrial morphology [214]. A mild
overexpression of OPA1 also protected against cardiac ischemic
injurymeasured in the form of reduced LDH release in 5months
old mice subjected to a Langendorff model of 40 min of ische-
mia followed by 15 min of reperfusion [215]. Whether this
modest expression of the long form of OPA1 (∼10% in
OPA1tg hearts versus ∼0.6% of total OPA1 in WT) is able to
reduce infarct size in an in vivo model of myocardial infarction
remains to be investigated. The role of the mitochondrial-
shaping proteins in susceptibility of the adult heart to acute IRI
is complex and not easily determined, further complicated by
the lack of an OPA1 or Mfn-specific activator.
Left Ventricular Hypertrophy
Mitochondrial Fission Proteins
The development of left ventricular hypertrophy (LVH) has
been linked to fragmentation of the mitochondria and en-
hanced mitophagy, due to an upregulation of Drp1 in a cell
model of phenylephrine-induced cardiomyocyte hypertrophy
[174, 177]. In order to prevent the development of LVH,
Givvimani et al. employed mdivi-1 to maintain the mitochon-
drial network and prompt the release of pro-angiogenic factors
(CD31 and VEGF) while reducing collagen deposition [174],
effects that were mirrored a year later in a quantitative
phosphoproteomics study using myocardial samples at differ-
ent time points following transverse aortic banding (TAB)
[216]. The hypertrophic response and oxygen consumption
were reduced in response to treatment with mdivi-1 while
the absence of mdivi-1 saw phosphorylation of DRP1 S622
and subsequent mitochondrial translocation in TAB-treated
mouse hearts and phenylephrine -treated rat neonatal
cardiomyocytes [216]. These findings suggest a potential ther-
apeutic strategy in acute inhibition of mitochondrial fission
proteins to salvage LV hypertrophy.
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Mitochondrial Fusion Proteins
MEK1/2–Erk1/2 expression is upregulated in LVH leading to
a proliferation of VSMC, a phenomenon inhibited by Mfn2
(formerly known as hyperplasia suppressor gene or HSG)
[217]. The same group used different experimental models
of LVH (phenylephrine induced LVH in neonatal rat
cardiomyocytes, spontaneously hypertensive rats, β2-
adrenergic transgenic mice, and pressure overload LVH by
transverse aortic constriction) to determine the downregula-
tion of Mfn2 and upregulation of Erk1/2 [217]. Angiotensin-
II treatment in neonatal rat myocytes similarly decreased ex-
pression of Mfn2 while elevating Akt levels. Over-expressing
MFN2 reversed the angiotensin-ii-induced LVH in both neo-
natal cardiomyocytes and the intact rat heart [218]. In mice
with cardiac-specific Mfn2 KO, the downregulation of Mfn2
impairs tethering of mitochondria to ER and subsequent Ca2+
signalling [9, 99]. Using the model of transverse aortic
constriction (TAC), Piquereau et al. demonstrated that a partial
deficiency in OPA1 also increases the susceptibility to LVH
and cardiac dysfunction, albeit whether resuming the levels of
OPA1 could rescue this phenotype is unknown [206].
Anthracycline Cardiomyopathy
The aetiology of myocardial contractile dysfunction induced
by anthracycline cardiotoxicity is unclear, althoughmitochon-
drial dysfunction and the production of ROS have been impli-
cated. Marechal et al. [219] demonstrated the presence of mi-
tochondrial fragmentation in hearts subjected to doxorubin,
and this change in mitochondrial morphology could be
prevented by the MPTP inhibitor, CsA. The importance of
mitochondrial fission to the pathophysiology of doxorubicin
cardiomyopathy was investigated by Gharanei et al. [172],
who found that treatment with the Drp1 inhibitor, mdivi-1,
attenuated mitochondrial fragmentation, prevented the cardiac
dysfunction and increase inMI size induced by doxorubicin in
the isolated rat heart, indicating the therapeutic potential for
inhibiting mitochondrial fission as a strategy for preventing
doxorubicin cardiomyopathy. Crucially, mdivi-1 was found to
have no effect on survival of a cancer cell line.
Vascular Effects of Mitochondrial Fusion and Fission
Proteins
Mitochondrial Fission Proteins
In native non-proliferative vascular smooth muscle cells
(VSMC), the mitochondria are static and mainly ovoid in shape
whereas during proliferation, the mitochondria become more
mobile with varying shapes [220]. Angiotensin II stimulation
of the cells activates Drp1 which will then interact with PKC-δ
and subsequent MEK1/2–ERK1/2 signalling cascade and
MMP2 [221]. Hyperproliferation of VSMCs also constitutes a
pathogenic mechanism in diabetic vascular complications, asso-
ciated with increased ROS leading to excessive Drp1- mediated
mitochondrial fission [222]. Inhibiting Drp1 via mdivi-1 im-
paired the proliferative response [221, 222]. Similarly, the pres-
ence of a positive feedback of ROS/mROS-DRP1 contributes to
the suppression of pulmonary arterial smooth muscle cells
(PASMC) apoptosis in hypoxic pulmonary vascular remodel-
ling, a phenomenon circumvented by the use of ROS inhibitors
such as N-acetylcysteine and mitochondrial-derived ROS inhib-
itor TEMPO [223]. The mechanism underlying pulmonary ar-
terial hypertension (PAH) lies in the hyperproliferation of the
PASMC, during which mitochondria divide to ensure equal re-
distribution. Fragmentation of the mitochondria during
hyperproliferation is due to an upregulation of Drp1 and down-
regulation of Mfn2, coupled with Cyclin B1/CDK1 phosphory-
lation of Drp1 at Ser-616. Reversal of PAH was achieved using
the small molecule inhibitor of Drp1 – mdivi-1 [60].
Mitochondrial Fusion Proteins
Originally known as a hyperplasia suppressor gene (HSG),
Mfn2 functions to inhibit VSMC proliferation in different
vasculo-proliferative conditions due to PKA-induced phos-
phorylation of Mfn2 at Ser442 [224, 225]. Over-expression of
Mfn2 in an experimental animal model of angioplasty balloon-
induced neointimal injury was found to inhibit VSMC prolif-
eration, oxidized LDL and subsequent atheroma formation and
carotid artery restenosis. Down-regulating Mfn2 conversely,
enhanced VSMC proliferation, coupled with an increase in
fatty acid oxidation and decrease in glucose oxidation.
Conflicting data where down-regulation of Mfn2 in HeLa cells
or T/G HA-VSMC cells suppressed proliferation has also been
shown where interrupted autophagosome-lysosome fusion and
impaired bioenergetics are the underlying factors [226].
During hypoxia-induced pulmonary hypertension in rats,
downregulation of Mfn2 activates the PI3K/Akt pathway,
thereby causing more cells to enter the S + G2/M phase of
the cell cycle and inhibiting the mitochondrial apoptosis path-
way [227]. These observations suggest that modifications in
mitochondrial morphology and bioenergetics may underlie
the hyperproliferative features of the VSMC, although the op-
timum balance of Mfn2 and associated mechanisms determine
the endpoint of whether activation or suppression of prolifera-
tion occurs. In the settings of PAH, bothMfn2 and PGC-1alpha
have been found to be down-regulated in PASMCs. Over-
expression of Mfn2 reversed the phenotype of PAH.
Similarly, both Mfn2 and PGC-1α were down-regulated in
PASMC in two different experimental models of PAH, and in
patients with PAH while Mfn2 reversed this phenotype. This
seems to implicate Mfn2 as a novel therapeutic target for PAH
[60], although whether preventing mitochondrial fission via the
use of mdivi-1 may be beneficial remain to be determined.
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Other Cardiac Conditions
Intriguingly, a recent experimental study by Sharp et al. [228]
has demonstrated that pharmacological inhibition of Drp1
using mdivi-1 improved time to return of spontaneous circu-
lation and hemodynamics, thereby resulting in improved sur-
vival and neurological outcomes, in a murine model of cardiac
arrest. Another interesting example is the work by Sumida
et al. [229] where they showed that mouse kidney subjected
to acute IRI induced mitochondrial fragmentation in the heart,
resulting in apoptosis and cardiac dysfunction, the effects of
which could be reverse by pharmacological inhibition of Drp1
using mdivi-1.
Diabetes
In obesity and type 2 diabetes (DM), the loss of mitochondrial
function inwhite adipose tissue is associated with a reduction in
whole body insulin sensitivity. It has been demonstrated in the
kidneys of streptozotocin-induced diabetic mice that there is an
upregulation of translocase of inner mitochondrial membrane
44 (Timm44) [230]. Timm44 anchors mitochondrial heat-
shock protein 70 to the translocase of inner mitochondrial
membrane 23 complex and facilitates the import of
mitochondria-targeted pre-proteins into the mitochondrial ma-
trix. Over-expression of Timm44 in mice fed high-fat/high-su-
crose chow protects from type 2 diabetes and obesity.
Adipocyte size and pro-fission proteins were reduced while
the pro-fusion proteins were induced when the mice were fed
standard chow [230]. The discrepancy behind these varying
levels of mitochondrial-shaping proteins in these mice when
fed different diets remains unexplained although mitochondria
ultimately became elongated.
Mitochondrial biogenesis remains unperturbed in the dia-
betic myocardium, in accordance with the absence of a differ-
ence in citrate synthase activities and PGC1-α protein expres-
sion [231]. Electron microscopy imaging of right atrial tissue
sections also showed no difference in interfibrillar mitochon-
drial density between diabetic and nondiabetic patients [231].
However, a shift toward smaller cardiac mitochondria was
observed in DM with a significantly lower mean mitochon-
drial length (1.14 μm) in diabetic versus (1.41 μm) in nondi-
abetic patients, due to a lower expression level of Mfn1 [231].
Interestingly, the content of myocardial MFN1 protein corre-
lated negatively with HbA1C concentrations. Autophagy
levels in the diabetic myocardium remained normal as well,
albeit Atg5 was significantly decreased [231]. These observa-
tions established the association of mitochondrial dysfunction
(mitochondrial fragmentation with decreased Mfn1) with de-
creased contractile performance in cardiac muscle of diabetic
patients before the onset of clinical cardiomyopathy. Obesity,
conversely, was not associated with any major perturbation of
mitochondrial function [231], although a study conducted in
the same year using high-fat diet -induced obese mice showed
the opposite [232]. A recent study also showcased the Drp1
monitoring of the mitochondrial network which is important
for glucose-stimulated insulin secretion in pancreatic beta
cells [233]. The optimum balance between fusion and fission
may, thus, govern the proper function of the pancreatic beta
cells and susceptibility to diabetes.
The presence of diabetes has been reported to render the
heart resistant to cardioprotective strategies such as ischemic
preconditioning and postconditioning. Yu et al. [234] found
that hyperglycemia blocked the cardioprotective effect elicited
of sevoflurane postconditioning by inducing mitochondrial
fission in neonatal rat cardiomyocytes, an effect which was
reversed using the Drp1 inhibitor, mdivi-1.
Therapeutic Targeting of Mitochondrial Fusion
and Fission Proteins
A number of strategies have been investigated to modulate
mitochondrial morphology including: genetic approaches
such as micro-RNAs [235]; upregulation of heme
oxygenase-1 (HO-1) to mediate mitochondrial quality control
[236]; restoration of Connexin43 networks [237]; and even
exercise to upregulate mitochondrial biogenesis factors
[238]. Remote ischemic preconditioning (RIPC) has been
shown to induce upregulation of OPA1 [214], and sevoflurane
postconditioning has been reported to suppress the decline of
OPA1 and increase in f Drp1 and Parkin induced by IRI [234].
Pharmacological interventions to target mitochondrial mor-
phology have included the use of melatonin [239, 240],
Tribulus terrestris L. fruit methanol extract [241],
mitochondria-targeted molecules MitoQ and SS31 that have
been shown to upregulate the pro-fusion proteins while down-
regulating the pro-fission proteins as well as inducing the mi-
tochondrial biogenesis genes PGC1α, PGC1β, Nrf1, Nrf2 and
TFAM [242], coenzyme Q10 to rescue loss of Mfn2-associated
respiratory impairment [243], resveratrol or SRT1720 to induce
Fig. 3 Image showing the co-dependency of both mitochondrial fusion
and fission in cardiac health and disease. Changes in mitochondrial
morphology in the form of fusion and fission can affect autophagy,
calcium signaling, ROS generation, mitochondrial energetics and
MPTP opening, all of which can impact on cardiac health and disease
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SIRT1 [213] or even metformin to inhibit ROS-associated mi-
tochondrial fission by upregulating Drp1 phosphorylation (Ser
637) in an AMPK-dependent manner, and then suppressing ER
stress [244]. The GLP-1 peptide-mimetic exenatide which has
been used for the treatment of type 2 diabetes prevents neoin-
timal layer formation in response to endothelial damage and
atherosclerotic lesion formation in aortic tissue. Torres et al.
have shown that GLP-1 induced a Ser-637 phosphorylation in
the mitochondrial fission protein Drp1, and decreased Drp1
mitochondrial localization, thereby inhibiting VSMCmigration
and proliferation [245].
Drugs that have been documented to protect the heart by
inhibiting the MPTP such as cyclosporine-A may well serve
to modulate mitochondrial morphology, although this needs to
be investigated. Similarly, although well-known mitochondri-
al morphology modulators such as mdivi-1 have been shown
to protect the heart against acute IRI, their potential off-target
effects and efficacy in a large animal model and humans re-
mains to be tested. The optimum time to modulate mitochon-
drial morphology during the course of cardiac dysfunction
progression to achieve a beneficial effect is not easy to deter-
mine. The drug delivery vehicle which may affect the potency
of the drug is another crucial factor to be taken into account. In
addition, one should realize that the hope of conferring
cardioprotection by simply modulating mitochondrial mor-
phology towards a defined phenotype may not be beneficial
in the long-term given that it will interfere with mitochondrial
homeostasis by disturbing the balance of mitochondrial fusion
and fission (see Fig. 3) [246].
Conclusions
Emerging studies suggest that changes in mitochondrial mor-
phology occur in different cardiac disease and pharmacological
targeting of the mitochondrial fusion and fission proteins may
provide a novel therapeutic strategy for treating cardiac diseases
such as acute myocardial infarction, LVH, PAH, and heart fail-
ure. However, it is important to take into consideration the
pleiotropic roles of themitochondrial shaping proteins especial-
ly the fusion proteins, Mfn2 and OPA1, when targeting the
mitochondrial shaping proteins as a treatment for cardiac dis-
ease. Furthermore, although acute inhibition or activation of the
shaping proteins may be beneficial in certain cardiac diseases,
the chronic inhibition or activation of either mitochondrial fu-
sion or fission proteins may have detrimental off-target effects.
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